136658-53-2

Basic information

• Product Name: (R)-2-Amino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide; hydrochloride
• Synonyms: (R)-2-Amino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide; hydrochloride
• CAS NO: 136658-53-2
• Molecular Weight: 343.856
• Mol File: 136658-53-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-2-Amino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide; hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Amino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide; hydrochloride(136658-53-2)
• EPA Substance Registry System: (R)-2-Amino-3-(1H-indol-3-yl)-N-((R)-1-phenyl-ethyl)-propionamide; hydrochloride(136658-53-2)

Safety Data

• Hazardous Substances Data: 136658-53-2(Hazardous Substances Data)

Upstream product

• 5241-64-5 Boc-D-Trp-OH 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 127369-26-0 [(R)-2-(1H-Indol-3-yl)-1-((R)-1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 127368-63-2 Quinoline-3-carboxylic acid [(R)-2-(1H-indol-3-yl)-1-((R)-1-phenyl-ethylcarbamoyl)-ethyl]-amide 

Relevant articles and documents

Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors

The intriguing structural similarities of glutamic acid based cholecystokinin (CCK) antagonists (A-64718 and A-65186) and the benzodiazepine CCK antagonist MK-329 (L-364,718) have been reported. Efforts to include the weak CCK antagonist benzotript into this construct utilizing a similar approach have resulted in a novel series of benzotript-based hybrid antagonists N(α)-(3'-quinolylcarbonyl)-(R)-tryptophan di-n-pentylamide (9, A-67396), N(α)-(4',8'-dihydroxy-2'-quinolylcarbonyl)-(R)-tryptophan di-n-pentylamide (23, A-70276), and N(α)-(3'-quinolylcarbonyl)-(R)-5'-hydroxytryptophan di-n-pentylamide (36, A-71134) which possess respectively binding affinities of 23, 21, and 11 nM for the pancreatic CCK-A receptor and which inhibit CCK8-induced amylase secretion. Compound 9 possesses a selectivity of > 500-fold for the pancreatic CCK-A receptor over the CCK-B receptor.